Wells Fargo
BCDA icon

Wells Fargo’s BioCardia BCDA Stock Holding History

Wells Fargo’s Portfolio BCDA Stock Details BCDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7
Closed -$44 – 6925
2024
Q1 		$44 Hold
7
– – ﹤0.01% 6857
2023
Q4 		$65 Buy
7
+1
+17% +$8 ﹤0.01% 6874
2023
Q3 		$40 Sell
6
-1
-14% -$17 ﹤0.01% 6977
2023
Q2 		$272 Buy
7
+1
+17% +$31 ﹤0.01% 6615
2023
Q1 		$170 Hold
6
– – ﹤0.01% 6822
2022
Q4 		$178 Hold
6
– – ﹤0.01% 6646
2022
Q3 		$0 Buy
6
+1
+20% +$26 ﹤0.01% 6654
2022
Q2 		$0 Hold
5
– – ﹤0.01% 6795
2022
Q1 		$0 Hold
5
– – ﹤0.01% 7053
2021
Q4 		$0 Hold
5
– – ﹤0.01% 7210
2021
Q3 		$0 Sell
5
-1
-17% -$49 ﹤0.01% 6966
2021
Q2 		$0 Buy
6
+1
+20% +$61 ﹤0.01% 6899
2021
Q1 		$0 Buy
5
+1
+25% +$62 ﹤0.01% 6880
2020
Q4 		$0 Buy
4
+2
+100% +$80 ﹤0.01% 6484
2020
Q3 		$0 Hold
2
– – ﹤0.01% 6328
2020
Q2 		$0 Hold
2
– – ﹤0.01% 6279
2020
Q1 		$0 Buy
+2
New +$124 ﹤0.01% 6193

Other funds holding BCDA

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
PP
Pingora Partners Wilson, Wyoming $169M AUM 56.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's BCDA Position: Q2 2024 in Review

Wells Fargo sold out of BioCardia (BCDA) in Q2 2024, closing a stake of 7 shares — an estimated $44 sold.

Wells Fargo first reported a position in BCDA in Q1 2020 and held it in 17 quarters. The position peaked at $272 in Q2 2023. 10 funds tracked by Wall St. Rank hold BCDA as of Q2 2024.

  • Wells Fargo reported no remaining BioCardia position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 7 BioCardia shares in Q2 2024, an estimated $44.
  • Wells Fargo first reported a position in BioCardia in Q1 2020 and held it in 17 quarters.
  • Wells Fargo's BioCardia position peaked at $272 in Q2 2023.
  • 10 funds tracked by Wall St. Rank held BioCardia as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.